Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

GENE - CHEMICAL INTERACTIONS REPORT

CRRD ID: 1602923
Species: Homo sapiens
CRRD Object: Gene
Symbol: MIR630
Name: microRNA 630
Acc ID: CHEBI:27899
Term: cisplatin
Definition: A diamminedichloroplatinum compound in which the two ammine ligands and two chloro ligands are oriented in a cis planar configuration around the central platinum ion. An anticancer drug that interacts with, and forms cross-links between, DNA and proteins, it is used as a neoplasm inhibitor to treat solid tumours, primarily of the testis and ovary. Commonly but incorrectly described as an alkylating agent due to its mechanism of action (but it lacks alkyl groups).
Chemical ID: MESH:D002945
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
MIR630decreases response to substanceEXP 6480464CTDMIR630 mRNA results in decreased susceptibility to Cisplatin

PMID:20145152
MIR630increases expressionEXP 6480464CTDCisplatin results in increased expression of MIR630, Cisplatin results in increased expression of MIR630 mRNA

PMID:20145152, PMID:21274007
MIR630multiple interactionsEXP 6480464CTD[Cisplatin results in increased expression of DICER1 protein] which results in increased metabolism of MIR630, [Cisplatin results in increased expression of MIR630] which results in decreased expression of BCL2 mRNA, [Cisplatin results in increased expression of MIR630] which results in decreased expression of BCL2L2 mRNA, [Cisplatin results in increased expression of MIR630] which results in decreased expression of YAP1 mRNA, [Cisplatin results in increased phosphorylation of TP63 protein alternative form] promotes the reaction [TP63 protein modified form binds to MIR630 promoter], Cisplatin promotes the reaction [MIR630 mRNA results in increased expression of CDKN1B protein], Cisplatin promotes the reaction [TP63 protein modified form results in increased expression of MIR630], MIR630 mRNA inhibits the reaction [Cisplatin promotes the reaction [BAX protein binds to BAX protein]], MIR630 mRNA inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein], MIR630 mRNA inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein], MIR630 mRNA inhibits the reaction [Cisplatin results in increased expression of BAX protein], MIR630 mRNA inhibits the reaction [Cisplatin results in increased phosphorylation of and results in increased activity of ATM protein], MIR630 mRNA inhibits the reaction [Cisplatin results in increased phosphorylation of H2AX protein], MIR630 mRNA inhibits the reaction [Cisplatin results in increased phosphorylation of TP53 protein]

PMID:20145152, PMID:21274007
Go Back to source page   Continue to Ontology report

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.